CGC Stock Overview
Engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Canopy Growth Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.99 |
| 52 Week High | CA$14.92 |
| 52 Week Low | CA$1.96 |
| Beta | 1.77 |
| 1 Month Change | -27.37% |
| 3 Month Change | -59.05% |
| 1 Year Change | -57.11% |
| 3 Year Change | -97.47% |
| 5 Year Change | -98.99% |
| Change since IPO | -93.97% |
Recent News & Updates
Crashing Canopy Growth Is Still Not A Buy
Jan 22Canopy Growth Remains Undervalued Amidst Cannabis Sector Uncertainty
Jan 11Recent updates
Crashing Canopy Growth Is Still Not A Buy
Jan 22Canopy Growth Remains Undervalued Amidst Cannabis Sector Uncertainty
Jan 11Avoid Canopy Growth
Nov 10Canopy Growth: Weak Fundamentals And Growth Acceleration Challenges
Oct 05Canopy Growth: Dilution, Executive Turnover, Cannabis Rescheduling Delay End High
Aug 27Canopy Growth: Cannabis Rally Loses Steam On Long-Term Uncertainty (Hold)
Jun 17Canopy Growth: Another Ugly Cannabis Report
Jun 03Canopy Growth Set For U.S. Cannabis Markets
Apr 26Canopy Growth Is Climbing, But It Won't Last
Mar 22Canopy Growth: Reiterate Strong Sell, Dilutive Offering Likely First Of Many To Come
Feb 06Canopy Growth: Further Implosion Is Now A Matter Of When Not If
Jan 29Avoid Canopy Growth After Failed Equity Sale
Jan 14Canopy Growth (Nasdaq:CGC): Further Dilution Seems Inevitable
Oct 13
Canopy Growth: Getting High
Oct 07Quick Takes: Tesla, Twitter, Carvana & More
Oct 06
Canopy Growth to sell Canadian retail operations, including Tokyo Smoke stores
Sep 27Canopy Growth: BioSteel Sizzles, Everything Else Fizzles
Aug 30What Is Canopy Growth's Stock Outlook After Earnings Miss?
Aug 23Shareholder Returns
| CGC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -10.4% | 2.3% | -0.9% |
| 1Y | -57.1% | 4.3% | 22.6% |
Return vs Industry: CGC underperformed the US Pharmaceuticals industry which returned 4.3% over the past year.
Return vs Market: CGC underperformed the US Market which returned 22.6% over the past year.
Price Volatility
| CGC volatility | |
|---|---|
| CGC Average Weekly Movement | 10.5% |
| Pharmaceuticals Industry Average Movement | 10.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CGC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CGC's weekly volatility has decreased from 21% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,029 | Luc Mongeau | www.canopygrowth.com |
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices.
Canopy Growth Corporation Fundamentals Summary
| CGC fundamental statistics | |
|---|---|
| Market cap | US$256.80m |
| Earnings (TTM) | -US$402.90m |
| Revenue (TTM) | US$192.96m |
1.3x
P/S Ratio-0.6x
P/E RatioIs CGC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CGC income statement (TTM) | |
|---|---|
| Revenue | CA$280.50m |
| Cost of Revenue | CA$193.61m |
| Gross Profit | CA$86.89m |
| Other Expenses | CA$672.58m |
| Earnings | -CA$585.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 07, 2025
| Earnings per share (EPS) | -4.79 |
| Gross Margin | 30.98% |
| Net Profit Margin | -208.81% |
| Debt/Equity Ratio | 108.7% |
How did CGC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 02:56 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Canopy Growth Corporation is covered by 28 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Capital Markets |
| Gaurav Jain | Barclays |